VgI-4 Activators

The chemical class termed VgI-4 Activators encompasses a diverse range of compounds that can influence the activity of VGLL4, a transcriptional co-factor known for its role in inhibiting the YAP-TEAD interaction within the Hippo signaling pathway.

Verteporfin, for instance, disrupts the YAP-TEAD interaction, which can enhance the inhibitory effect of VGLL4 on this interaction. Dasatinib, on the other hand, inhibits Src family kinases, which are known regulators of the Hippo pathway, thereby potentially influencing VGLL4's role. Statins, such as Lovastatin, by inhibiting HMG-CoA reductase, can influence the Hippo pathway and, in turn, VGLL4's function. Compounds like Forskolin, which elevate cAMP levels, and EGF, a modulator of various cell signaling pathways, can also have an impact on the Hippo pathway and VGLL4's function. LPA and S1P are lipid signaling molecules that regulate the Hippo pathway, thereby potentially affecting VGLL4's role. FTY720, a sphingosine analogue, and compounds like Latrunculin B and Jasplakinolide, which influence actin dynamics, can also modulate the Hippo pathway and VGLL4's function. Lastly, Rapamycin, an mTOR signaling inhibitor, and Y-27632, a ROCK inhibitor, can influence the Hippo pathway, thereby potentially affecting VGLL4's role.